Xiaozhou Yao

Summary

Affiliation: GlaxoSmithKline Research and Development
Country: USA

Publications

  1. ncbi Propranolol inhibits the human ether-a-go-go-related gene potassium channels
    Xiaozhou Yao
    Department of Biochemical and Analytical Pharmacology, Research and Development, GlaxoSmithKline, NC 27709, USA
    Eur J Pharmacol 519:208-11. 2005
  2. ncbi Predicting QT prolongation in humans during early drug development using hERG inhibition and an anaesthetized guinea-pig model
    X Yao
    Department of Biochemical and Analytical Pharmacology, GlaxoSmithKline, Research Triangle Park, NC 27709, USA
    Br J Pharmacol 154:1446-56. 2008

Detail Information

Publications2

  1. ncbi Propranolol inhibits the human ether-a-go-go-related gene potassium channels
    Xiaozhou Yao
    Department of Biochemical and Analytical Pharmacology, Research and Development, GlaxoSmithKline, NC 27709, USA
    Eur J Pharmacol 519:208-11. 2005
    ..The interaction between propranolol and hERG channels could lead to delayed cardiac repolarization and might be a molecular mechanism for the previously reported QTc prolongation when propranolol is overdosed...
  2. ncbi Predicting QT prolongation in humans during early drug development using hERG inhibition and an anaesthetized guinea-pig model
    X Yao
    Department of Biochemical and Analytical Pharmacology, GlaxoSmithKline, Research Triangle Park, NC 27709, USA
    Br J Pharmacol 154:1446-56. 2008
    ..The purpose of the present study was to develop and verify a reliable and relatively simple approach for assessing, during preclinical development, the propensity of drugs to prolong the QT interval in humans...